Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790101 · ClinicalTrials.gov registry record · Phase 4
Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
A Phase 4 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00790101: Clinical Trial Phase 4 study, sponsored by Sanofi.
NCT00790101 is a Phase 4 study that was terminated before completion, run by Sanofi. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00790101, a Phase 4 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.
Interventions
- OTHER Placebo
- DRUG Risedronate
- DRUG Raloxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-06 |
| Est. Completion | 2004-10 |
| Phase | Phase 4 |
Why NCT00790101 stopped before completion
NCT00790101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00790101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00790101 about?
NCT00790101 is a clinical study titled "Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation". This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.
What is the current status of trial NCT00790101?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2004-06. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00790101?
The interventions under investigation include: Placebo (OTHER), Risedronate (DRUG), Raloxifene (DRUG).
Who is sponsoring clinical trial NCT00790101?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00790101's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia